AI Agent Development Company in Cambridge

A single-workflow prototype and a regulated multi-agent system are different products, and the distance between them is the whole Cambridge range: a scoped agent proof of concept at Cambridge rates over six to eight weeks, covering workflow archaeology, a task graph, a working prototype on Claude Sonnet or GPT-4o, and an evaluation harness on a frozen golden set, a production agent (biotech regulatory drafting, SOC triage, finance approval routing) including LangGraph orchestration, retrieval over a client-owned vector store, human-in-the-loop gating, and a DPIA aligned to ICO AI guidance, or a multi-agent system coordinating across CMR Surgical-style operational complexity or AstraZeneca-style regulatory document pipelines. Cambridge rates carry a Silicon Fen premium over Manchester or Leeds because the local PhD talent pool sets expectations, but our Edmonton and Chandigarh hubs keep margins reasonable. Fixed fee only, with the eval harness and quarterly drift review included for the first year so you are not paying us hourly to discover regressions in your own agent.

Sometimes, and the answer depends on whether the agent makes a decision with legal or similarly significant effect without meaningful human input. Article 22 of the UK GDPR restricts solely automated decisions on individuals, and the ICO's 2023 guidance on AI and data protection extends that scrutiny to agentic workflows where the human review is a rubber-stamp rather than a substantive checkpoint. Our Cambridge builds default to a documented human-in-the-loop pattern, with a reviewer who can see the agent's reasoning trace, the retrieved sources, and the tool calls executed. For high-stakes agents (credit-adjacent decisions inside Featurespace-style fraud workflows, patient-impacting drafts in AstraZeneca-adjacent regulatory work) we run a Data Protection Impact Assessment, document the lawful basis under Article 6, and set up an ICO-style explainability surface. We do not ship a Cambridge agent that takes a binding action on a person without a designed override path and an audit log capable of surviving an ICO inspection.

Hallucination tolerance in Cambridge biotech work is near zero, especially for anything touching MHRA submissions, HRA ethics applications, or ATMP regulatory pathways. We do four things. First, retrieval-grounded generation with citation enforcement, so the agent cannot draft a paragraph without quoting a source from the client's Veeva Vault, Benchling, or document store. Second, structured output contracts with JSON schema validation, so a free-form hallucination cannot slip through into a downstream tool call. Third, a frozen golden eval set scored on Braintrust or LangSmith, refreshed quarterly, so model upgrades from Anthropic or OpenAI cannot silently degrade behaviour. Fourth, a confidence-routing pattern where low-confidence outputs escalate to a human reviewer rather than auto-completing. We have applied this to literature surveillance agents on PubMed and MHRA Yellow Card data, and the structured-citation-plus-eval combination has kept measurable hallucination rates below the threshold Cambridge Biomedical Campus quality teams accept.

Yes. Benchling integration runs through their official REST and GraphQL APIs for entity registration, assay results, and notebook entries, and we wrap those calls inside an agent tool layer that enforces lab-defined permissions before the agent can write anything. Veeva Vault integration covers the QualityDocs, RIM, and Clinical Vaults using Vault's REST API plus VQL queries, and we keep the agent in read-only mode for regulated documents unless explicit human approval is logged for a write. For chemistry workflows we use RDKit and the ChEMBL API. For protein and structural work we connect to AlphaFold and the PDB. For NHS-adjacent medtech projects we use HL7 FHIR through NHS Digital's APIM gateway. Each integration ships with rate-limit handling, retry-on-failure semantics, and a tool-call audit log that maps cleanly onto GxP expectations Cambridge pharma and ATMP teams already have for any system touching submission-grade data.

Yes. We do not replace Darktrace or Featurespace ARIC. We build SOC triage and fraud-investigation agents that consume their alerts and either deduplicate, enrich, or escalate inside Microsoft Sentinel, Splunk, or a client's case management tool. Typical Cambridge build: an agent that ingests Darktrace network anomaly alerts, correlates them against Microsoft Defender XDR signals and CrowdStrike Falcon endpoint data, drafts an incident summary, and proposes a containment action that a human analyst approves before execution. For fraud, we have built agents that take Featurespace-style transaction risk scores, pull historical context from Snowflake or BigQuery, and draft a case narrative for an analyst to confirm or reject. Both patterns inherit the prompt-injection defences and red-team tests we already run against agent tooling, and they ship with a kill-switch and rate limiter so a misbehaving agent cannot flood a SOC queue or auto-block legitimate traffic at scale.

A standard Cambridge production agent (regulatory drafting, SOC triage, internal operations copilot) takes twelve to eighteen weeks end-to-end. Weeks one and two are workflow archaeology and task graph design. Weeks three to six build the core retrieval and reasoning loop on Claude Sonnet, GPT-4o, or self-hosted Llama 3.3, with a first eval set in place by week four. Weeks seven to ten add tool integrations to Benchling, Veeva Vault, Microsoft Sentinel, or whichever client systems are in scope, and refine the human-in-the-loop gating. Weeks eleven to fourteen run shadow mode in production, comparing agent output to human baseline daily, with iteration on prompts and routing. Weeks fifteen to eighteen are gradual rollout under monitoring, drift detection, and incident runbooks. Multi-agent systems and anything touching MHRA submissions or HRA-approved studies add four to eight weeks for the additional documentation, DPIA, and validation testing Cambridge regulated clients expect.

Often yes, but the rules tightened in April 2024. The merged RDEC scheme now gives a 20 percent above-the-line credit on qualifying R&D, with an enhanced rate (ERIS) for R&D-intensive SMEs at 14.5 percent payable. Eligible activity for AI agent work generally includes novel orchestration design, evaluation methodology development, retrieval architecture experimentation, and any algorithmic uncertainty resolved through systematic investigation. Routine prompt tweaking, off-the-shelf API integration, and standard tool wiring are not eligible. We deliver time-tracked logs, technical narratives mapped to HMRC's CIRD80300 guidance, and a failed-hypothesis log that supports a defensible claim. Cambridge biotech clients sometimes stack the Patent Box on downstream commercialisation if the agent feeds a patented process. We do not file the claim ourselves. We hand the documentation to your R&D tax advisor (Ayming, ForrestBrown, or a Cambridge boutique like Hamilton Wood) and they assemble the HMRC submission.

Cambridge AI consultancies on Hills Road and around Cambridge Science Park bill £1,500 to £2,500 per developer day and often subcontract production engineering. Big 4 advisory firms (Deloitte, PwC, EY, KPMG) bring brand and procurement comfort but rarely ship the production-grade evaluation and prompt-versioning discipline a working agent needs. We ship at fixed fee from our Chandigarh hub across Cambridge mornings and our Edmonton hub on Mountain Time across Cambridge late-afternoons, which gives you a synchronous standup window plus extended build hours without the rate of a Cambridge boutique. We have shipped agents in regulated environments where the audit trail had to survive ICO inspection, MHRA scrutiny, or HRA ethics review. We will tell you up front when a problem is research-grade and belongs with a Vector Institute-style academic partner or a Microsoft Research Cambridge collaboration rather than a delivery engagement, because pretending otherwise costs Cambridge clients their year.